Member Scientific Advisory Board
HMH is New Jersey’s largest Healthcare system (17 hospitals / 38000 employees) and its flagship oncology program, John Theurer Cancer Center is recognized as state’s premier program by US News and World Reports. JTCC is a member of the NCI designated Lombardi Comprehensive Cancer Center Consortium and also a member of the Memorial Sloan Kettering - Hackensack Meridian Health partnership.
Dr. Goy leads the Lymphoma Program at JTCC and is widely known for his work particularly in aggressive lymphoma and mantle cell lymphoma, especially around novel therapies and cell therapies/CAR T cells. He has served on the NCI steering committee for lymphoma and on the Scientific Advisory Board of the Lymphoma Research Foundation. Dr. Goy has published more than 200 peer reviewed papers and serves as reviewer for many journals in the field including the New England Journal of Medicine, the Journal of Clinical Oncology, and Blood, among others.
Dr Goy believes we are at an inflection point in medicine due to unprecedented combination of rapid progress in science and discovery, but also technology which will help reshape both health and healthcare delivery. He co-chaired the Global Council on the Future of Health and Healthcare for the World Economic Forum from 2015 to 2019.
After completing medical school at University Joseph Fourier School of Medicine in Grenoble, France, Dr Goy received his training in Hematology Oncology and Immunology at The University Hospital System and Pasteur Institute in Paris. He then was on Faculty at Memorial Sloan-Kettering and M.D. Anderson Cancer Center together for 15 years before joining John Theurer Cancer Center in 2005.